PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...

A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...

Researchers from Shenzhen University and affiliated organizations detailed the preclinical characterization of a synergistic intravesical instillation of fenbendazole (FBZ) and CRISPR-Cas13a-based ...

RAD-SG: Adaptive radiation therapy with concurrent sacituzumab govitecan (SG) for bladder preservation in patients (pts) with muscle invasive bladder cancer (MIBC). A phase 2/3 study of bicycle toxin ...

PRINCETON, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, ...

Credit: Getty Images. 5α-reductase inhibitors are widely used to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. Use of 5α-reductase inhibitors (5-ARIs) prior to a bladder ...

Association between combination of VI-RADS based on T2WI and morphological features and pathological outcome and prognosis in bladder cancer. This is an ASCO Meeting Abstract from the 2025 ASCO ...